To appraise the clinical and cost effectiveness of tildrakizumab within its marketing authorisation for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Status Proposed
Process STA
ID number 1060

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
25 May 2017 - 23 June 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance